TrialPath
Recruiting

FES BPET-DBT in Newly Diagnosed Breast Cancer

NCT05659797 · Abramson Cancer Center at Penn Medicine
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Pilot Study Evaluating the Uptake of [18F]Fluoroestradiol (FES) BPET/DBT in Primary Breast Cancer to Measure the Localized Extent of Estrogen Receptor Positive Disease
About this study
The FES-BPET/DBT imaging session will include an injection of approximately 6 mCi (expected range of injected dose is 3-7 mCi) FES. Pilot data will be collected to evaluate image quality of FES-BPET/DBT in primary breast cancer. Size and focality of breast cancer extent as measured by FES-BPET/DBT will be compared to disease extent on standard breast imaging modalities. FES uptake on BPET/DBT, as measured by SUV, will be compared to ER expression by immunohistochemistry (IHC) on biopsy specimens. In addition, all subjects in this study will be recruited to the open ended Penn protocol titled 'Evaluation of Long-Axial Field-of-View Positron Emission Tomography Scanner,' IRB #843546. In those subjects who consent to this proposed study as well as #843546, assessment of disease extent on FES-BPET/DBT will be compared to that on whole body PET. Of note, those subjects who also consent to #843546 will not undergo any additional injected dose of FES radiotracer. This preliminary study seeks to evaluate FES-BPET/DBT as a preoperative imaging assay of ER-positive breast cancer disease extent within the breast.
Eligibility criteria
Inclusion Criteria: 1. Participants will be ≥ 18 years of age. 2. Known ER positive (by immunohistochemistry) breast cancer. 3. At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. mammogram, ultrasound, MRI, CT, FDG-PET/CT). Only one type of imaging is required to show a lesion. 4. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: 1. Females who are pregnant or breast feeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to PET imaging.. 2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. 3. Currently taking tamoxifen or raloxifene 4. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Study design
Enrollment target: 20 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2023-10-02
Estimated completion: 2028-01
Last updated: 2026-02-27
Interventions
Device: BPET/DBT imagingDrug: 18F-FES
Primary outcomes
  • Uptake of FES on BPET (6 weeks)
  • Image quality (6 weeks)
  • Image artifacts (6 weeks)
Sponsor
Abramson Cancer Center at Penn Medicine · other
Contacts & investigators
ContactErin o Schubert · contact · erin.schubert@pennmedicine.upenn.edu · 2155736569
ContactHannah Straughn · contact · hannah.straughn@pennmedicine.upenn.edu
InvestigatorChristine Edmonds, MD · principal_investigator, Abramson Cancer Center at Penn Medicine
All locations (1)
University of PennsylvaniaRecruiting
Philadelphia, Pennsylvania, United States
FES BPET-DBT in Newly Diagnosed Breast Cancer · TrialPath